The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

3CD16a/Fcgr3A, C-terminal Avi-HIS-tag, in vivo biotinylated

$326.43$1,171.80 excl. VAT

Soluble CD16A/Fcgr3a, C-terminally HIS-Avi-tagged, produced in HEK293 cells and in vivo mono-biotinylated. Recombinant FcγRs can be used to monitor immune processes, providing a time-efficient and reproducible alternative to laborious cell-based assays.

SKU: REC32069 Categories: , Tag:

3CD16a/Fcgr3A, C-terminal Avi-HIS-tag, in vivo biotinylated

Soluble CD16A/Fcgr3a, C-terminally HIS-Avi-tagged, produced in HEK293 cells and in vivo mono-biotinylated. Recombinant FcγRs can be applied in multiplex assays to characterise IgG subclass-specific affinities supporting research into immune therapies, including therapeutic antibodies and novel vaccines.

 

PRODUCT DETAILS – 3CD16a/Fcgr3A , C-terminal Avi-HIS-tag, in vivo biotinylated

  • Recombinant human 3CD16a/Fcgr3A protein, in vivo biotinylated
  • Proteins contain a C-terminal Avi-HIS-tag
  • NCBI Accession number: P08637-1
  • Proteins were expressed in HEK293 cells and purified from culture supernatant by immobilised metal affinity chromatography.
  • Presented as Liquid

Contact us for more details: nac.contact@lgcgroup.com

Useful links

Junker, F., Gordon, J. and Qureshi, O. (2020) “FC gamma receptors and their role in antigen uptake, presentation, and T cell activation,” Frontiers in Immunology, 11. Available at: https://doi.org/10.3389/fimmu.2020.01393.

Nath, N. et al. (2022) “A homogeneous bioluminescent immunoassay for parallel characterization of binding between a panel of antibodies and a family of Fcγ receptors,” Scientific Reports, 12(1). Available at: https://doi.org/10.1038/s41598-022-15887-z.

REC32069 CoA#23010616P